Foundayo (Orforglipron) FDA Approved: The First GLP-1 Weight Loss Pill You Can Take Anytime
On April 1, 2026, the FDA approved Foundayo (orforglipron) — the first non-peptide, oral GLP-1 medication for weight loss. Made by Eli Lilly, it's a once-daily pill that can be taken any time of day, with or without food, with no water restrictions. This is a fundamentally different kind of GLP-1 medication, and it could reshape the market.
What Is Foundayo and Why Is It Different?
Foundayo (orforglipron) is a small-molecule, non-peptide GLP-1 receptor agonist. That technical description matters because every other GLP-1 on the market — Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda — is a peptide. Peptides are large, fragile molecules that your stomach acid destroys, which is why most GLP-1s require injection.
Oral Wegovy (approved December 2025) solved part of this problem by packaging the semaglutide peptide with an absorption enhancer (SNAC), but it still requires fasting — you must take it on an empty stomach with limited water and wait 30 minutes before eating. Foundayo has none of these restrictions because it's not a peptide at all. It's a completely different type of molecule that naturally survives digestion.
| Feature | Foundayo (orforglipron) | Oral Wegovy (semaglutide) | Injectable Wegovy | Injectable Zepbound |
|---|---|---|---|---|
| Type | Small molecule pill | Peptide pill | Peptide injection | Peptide injection |
| Dosing | Once daily, anytime | Once daily, fasting required | Once weekly injection | Once weekly injection |
| Food restrictions | None | 30-min fast required | N/A | N/A |
| Refrigeration | Not needed | Not needed | May be needed | May be needed |
| Manufacturer | Eli Lilly | Novo Nordisk | Novo Nordisk | Eli Lilly |
| FDA approved | April 1, 2026 | December 2025 | June 2021 | November 2023 |
How Much Weight Can You Lose? Clinical Trial Results
Foundayo's clinical trials show meaningful weight loss, though less than the injectable GLP-1s. The key Phase 3 results:
ATTAIN-1 trial (Phase 3, 72 weeks, adults with obesity/overweight):
| Dose | Weight Loss at 72 Weeks | Achieved 10%+ Loss | Achieved 15%+ Loss |
|---|---|---|---|
| 36 mg (highest) | -12.4% | 54.6% | 36.0% |
| 12 mg | -9.3% | — | — |
| 6 mg | -7.8% | — | — |
| Placebo | -2.1% | 12.9% | 5.9% |
In the head-to-head ACHIEVE-3 trial (published in The Lancet, February 2026), orforglipron 36mg produced 73.6% greater weight loss than oral semaglutide 14mg over 52 weeks: -9.2% vs -5.3%. It also delivered superior blood sugar control (HbA1c reduction of -2.2% vs -1.4%).
What Does Foundayo Cost?
| Coverage Scenario | Monthly Cost | How to Get It |
|---|---|---|
| Commercial insurance + savings card | As low as $25/mo | Foundayo savings card from Eli Lilly |
| Self-pay (lowest dose) | $149/mo | LillyDirect or retail pharmacy |
| Self-pay (higher doses) | Up to $399/mo | LillyDirect or retail pharmacy |
| Medicare Part D (July 2026+) | $50/mo | Medicare GLP-1 Bridge program |
| TrumpRx MFN pricing | ~$346/mo average | Included in Lilly MFN deal |
Foundayo is available in six tablet strengths: 0.8mg, 2.5mg, 5.5mg, 9mg, 14.5mg, and 17.2mg. Like all GLP-1s, you start at the lowest dose and gradually escalate. LillyDirect began shipping on April 6, 2026, with broader retail pharmacy availability following.
Side Effects
The side effect profile is similar to other GLP-1s — primarily gastrointestinal, typically improving over time:
| Side Effect | Foundayo 36mg | Placebo |
|---|---|---|
| Nausea | 33.7% | 10.4% |
| Constipation | 25.4% | 9.3% |
| Diarrhea | 23.1% | 9.6% |
| Vomiting | 24.0% | 3.5% |
Discontinuation rates due to side effects were 10.3% at the highest dose vs 2.7% for placebo. About 59% of participants reported GI symptoms overall, though most were mild to moderate and improved during dose escalation. In the ACHIEVE-3 head-to-head trial, orforglipron had higher GI event rates than oral semaglutide (59% vs 37-45%).
Who Is Foundayo For?
Foundayo is approved for adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related health condition, as an addition to diet and exercise — the same criteria as Wegovy and Zepbound.
It's most compelling for patients who:
- •Refuse or fear needles — the #1 barrier to GLP-1 adoption
- •Tried oral Wegovy but struggle with the fasting/timing requirements
- •Want a simpler daily routine — take it whenever, with coffee, with meals, doesn't matter
- •Travel frequently — no refrigeration, no injection supplies needed
- •Prefer Eli Lilly's ecosystem (same company as Zepbound/Mounjaro)
If maximum weight loss is your priority and you're comfortable with injections, Zepbound (~22% loss) or the upcoming retatrutide (~29% in trials) will likely deliver more. Foundayo's value is convenience and accessibility, not raw efficacy.
How to Get Foundayo
- •LillyDirect (direct from manufacturer): Shipping started April 6, 2026. Self-pay pricing from $149/mo.
- •Telehealth providers: Several providers on our rankings are expected to add Foundayo to their offerings in the coming weeks.
- •Retail pharmacies: Broader availability rolling out throughout April-May 2026.
- •Insurance: Check with your plan. Eli Lilly's savings card can reduce copays to $25/mo with commercial coverage.
Check our provider rankings to see which telehealth platforms offer Foundayo, or use our cost calculator to estimate what you'd pay with your specific insurance.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any medication. Information is current as of the publication date but may change.
Affiliate Disclosure: Some links in this article are affiliate links. We may earn a commission if you sign up through our links, at no extra cost to you.